Leukemia and lymphoma patients will have greater access to a ground-breaking new treatment, now that the federal government has subsidised the drug.
The treatment drug, Ibrutinib, would normally cost $187,390 on average per course of treatment, putting it beyond the reach of most patients.
However, the government’s decision to allocate $466 million Pharmaceutical Benefits Scheme is expected to save patients hundreds of thousands of dollars.
As a result, Member for Barker Tony Pasin said it would cost patients a maximum of $38.80 per treatment and just $6.30 for concessional patients from December 1.
“Since coming into Government, the Coalition has helped improve the health of Australians by adding around $7.5 billion worth of medicines to the PBS and the announcement today is further support for patients that need it,” he said.
“This new treatment will provide much needed support to patients who don’t respond to other initial treatments.”